The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Phasebio Pharmaceuticals, INC. on November 8, 2023. As per the order, the debtor?s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 90 days up to January 18, 2024 and March 18, 2024, respectively.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 49 | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PHAS.Q Stock
- News PhaseBio Pharmaceuticals, Inc.
- Fourth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.